An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells With Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 7
- 主要终点
- Ph-positive cells in stem cell compartments
研究概览
简要总结
A randomized multi-center study comparing the effect of dasatinib and imatinib on malignant stem cells in newly diagnosed chronic phase chronic myeloid leukemia (CML) patients. The research hypothesis is that treatment with dasatinib 100 mg daily (QD) results in greater and more rapid depletion of the Philadelphia (Ph) -positive stem cell pool within 6 months of therapy than imatinib 400 mg QD in newly diagnosed CML patients. The study duration is 18 months and approximately 40 patients will be recruited to the study.
详细描述
An Open-Label, Randomized, Multicenter Phase II Trial Comparing the depletion of malignant stem cells with Dasatinib vs. Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Estimated Number of Study Centers and Countries/Regions: Appr. 12 sites in 5 Nordic countries. Stem cell analyses will be performed in 4 Nordic centers (Helsinki, Lund, Oslo and Stockholm).
Study Phase: II
Research Hypothesis: Treatment with dasatinib 100 mg daily (QD) results in greater and more rapid depletion of the Philadelphia (Ph) -positive stem cell pool within 6 months of therapy than imatinib 400 mg QD in newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) patients.
Primary Objective: To compare the number of Ph-positive cells in the stem cell compartment in newly diagnosed CP CML patients treated with dasatinib 100 mg QD vs. imatinib 400 mg QD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients are able to provide written informed consent
- •Patients must have CML in CP which is defined by the presence of all of the following criteria:
- •< 15% blasts in peripheral blood (PB) and BM.
- •< 30% blasts plus promyelocytes in PB and BM.
- •< 20% basophils in the PB.
- •≥ 100 x 109/L platelets.
- •No evidence of extramedullary leukemia apart from hepatosplenomegaly
- •Ph+ or variants must be demonstrated by BM cytogenetics, FISH or PCR.
- •Previously untreated CML in CP, with the exception of hydroxyurea or anagrelide
- •Patients must be enrolled in this study within 90 days after the date of first being diagnosed with CML
- •ECOG Performance Status (PS) Score 0 - 1 (see Appendix 2)
- •Adequate hepatic function defined as: total bilirubin ≤ 2.0 times the institutional upper limit of normal (ULN) in absence of Gilbert type unconjugated hyperbilirubinemia; alanine aminotransferase (ALAT≤ 2.5 times the institutional ULN.
- •Adequate renal function defined as serum creatinine ≤ 2 times the institutional ULN.
- •Men and women, ages 18 years and older.
- •Adequate BM aspiration sample before the start of study treatment (i.e sample is sufficient for stem cell analysis)
- •Potentially fertile women must use an adequate method of contraception to avoid pregnancy throughout the study.
- •Potentially fertile women must have a negative serum or urine pregnancy test
排除标准
- •Fertile women who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study
- •Women who are pregnant or breastfeeding.
- •Men with fertile sexual partners who can or will not use an acceptable contraception method for the entire study
- •A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy.
- •Known pleural effusion at baseline.
- •Uncontrolled or significant cardiovascular disease
- •History of significant bleeding disorder unrelated to CML, including:
- •Prior chemotherapy for peripheral stem cell mobilization.
- •Inadequate BM aspiration sample due to marrow fibrosis or other reasons
- •Prior or concurrent malignancy
- •Severe psychiatric illness, imprisonment or mental impairment inflicting on ability to give informed consent
- •Abuse of alcohol, prescribed or illicit drugs
- •Evidence of digestive dysfunction that would prevent administration of study therapy by mouth.
- •Prohibited Treatments and/or Therapies
- •Any prior treatment with interferon
- •Any prior treatment with dasatinib
- •Any prior treatment with imatinib
- •Any other prior systemic treatments, with anti-CML activity [except for anagrelide, or hydroxyurea (HU)].
- •Patients currently taking drugs that are generally accepted to have a risk of causing Torsades de Pointes as described in Appendix 3.
研究组 & 干预措施
Imatinib
Standard treatment Imatinib 400mg OD
干预措施: Imatinib (Drug)
dasatinib
Dasatinib 100mg OD
干预措施: Dasatinib (Drug)
结局指标
主要结局
Ph-positive cells in stem cell compartments
时间窗: 6 months
proportion of Ph-positive cells in stem cell compartments (CD34+CD38neg and CD34+CD38+)
次要结局
- BCR-ABL RQ-PCR in blood(up to 18 months (1, 3, 6, 12 and 18 months))